Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Exelixis
Related studies linked through entity extraction aliases.
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pan Tumor Rollover Study
- Status
- RECRUITING
- Phase
- PHASE2
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
- Status
- TERMINATED
- Phase
- NA
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
- Status
- COMPLETED
- Phase
- PHASE1
Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
- Status
- COMPLETED
- Phase
- PHASE2
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1